Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era

Nitin Jain, Koen Van Besien

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

In the pre-tyrosine kinase (TKI) era, allogeneic stem cell transplant (allo-SCT) was the front-line treatment of choice for young patients with chronic myelogenous leukemia (CML). Today, imatinib is well established as front-line therapy for CML, with excellent long-term outcomes. This has changed the role of allo-SCT and the number of patients undergoing allo-SCT has declined dramatically. Allo-SCT is currently recommended for patients in accelerated/blast phase disease, those who have failed a second-generation TKI and those with TKI-resistant mutations such as T315I. The role of allo-SCT in the management of CML will require continual reappraisal as medical therapies continue to evolve.

Original languageEnglish (US)
Pages (from-to)1025-1048
Number of pages24
JournalHematology/Oncology Clinics of North America
Volume25
Issue number5
DOIs
StatePublished - Oct 1 2011

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem Cells
Protein-Tyrosine Kinases
Transplants
Blast Crisis
Therapeutics
Cell Count
Mutation
Imatinib Mesylate

Keywords

  • Allogeneic stem cell transplant
  • Chronic myelogenous leukemia
  • Imatinib
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Chronic Myelogenous Leukemia : Role of Stem Cell Transplant in the Imatinib Era. / Jain, Nitin; Van Besien, Koen.

In: Hematology/Oncology Clinics of North America, Vol. 25, No. 5, 01.10.2011, p. 1025-1048.

Research output: Contribution to journalReview article

@article{e104d4b1a177471b8f7d2b2b3253ed0a,
title = "Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era",
abstract = "In the pre-tyrosine kinase (TKI) era, allogeneic stem cell transplant (allo-SCT) was the front-line treatment of choice for young patients with chronic myelogenous leukemia (CML). Today, imatinib is well established as front-line therapy for CML, with excellent long-term outcomes. This has changed the role of allo-SCT and the number of patients undergoing allo-SCT has declined dramatically. Allo-SCT is currently recommended for patients in accelerated/blast phase disease, those who have failed a second-generation TKI and those with TKI-resistant mutations such as T315I. The role of allo-SCT in the management of CML will require continual reappraisal as medical therapies continue to evolve.",
keywords = "Allogeneic stem cell transplant, Chronic myelogenous leukemia, Imatinib, Tyrosine kinase inhibitors",
author = "Nitin Jain and {Van Besien}, Koen",
year = "2011",
month = "10",
day = "1",
doi = "10.1016/j.hoc.2011.09.003",
language = "English (US)",
volume = "25",
pages = "1025--1048",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Chronic Myelogenous Leukemia

T2 - Role of Stem Cell Transplant in the Imatinib Era

AU - Jain, Nitin

AU - Van Besien, Koen

PY - 2011/10/1

Y1 - 2011/10/1

N2 - In the pre-tyrosine kinase (TKI) era, allogeneic stem cell transplant (allo-SCT) was the front-line treatment of choice for young patients with chronic myelogenous leukemia (CML). Today, imatinib is well established as front-line therapy for CML, with excellent long-term outcomes. This has changed the role of allo-SCT and the number of patients undergoing allo-SCT has declined dramatically. Allo-SCT is currently recommended for patients in accelerated/blast phase disease, those who have failed a second-generation TKI and those with TKI-resistant mutations such as T315I. The role of allo-SCT in the management of CML will require continual reappraisal as medical therapies continue to evolve.

AB - In the pre-tyrosine kinase (TKI) era, allogeneic stem cell transplant (allo-SCT) was the front-line treatment of choice for young patients with chronic myelogenous leukemia (CML). Today, imatinib is well established as front-line therapy for CML, with excellent long-term outcomes. This has changed the role of allo-SCT and the number of patients undergoing allo-SCT has declined dramatically. Allo-SCT is currently recommended for patients in accelerated/blast phase disease, those who have failed a second-generation TKI and those with TKI-resistant mutations such as T315I. The role of allo-SCT in the management of CML will require continual reappraisal as medical therapies continue to evolve.

KW - Allogeneic stem cell transplant

KW - Chronic myelogenous leukemia

KW - Imatinib

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=80755189388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755189388&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2011.09.003

DO - 10.1016/j.hoc.2011.09.003

M3 - Review article

C2 - 22054733

AN - SCOPUS:80755189388

VL - 25

SP - 1025

EP - 1048

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 5

ER -